Document:

EX-10.13

 Exhibit 10.13 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS
BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 Standard Civitas Form 

Master Contract Services Agreement 
 Approved April 2011

 MASTER CONTRACT SERVICES AGREEMENT 

THIS MASTER CONTRACT SERVICES AGREEMENT (together with Appendix A and any Statement(s) of Work (as defined in Section 1), the
“Agreement”) is made on September 26, 2013, (the “Effective Date”) by and between Civitas Therapeutics, Inc., a Delaware corporation with an office at 190 Everett Avenue, Chelsea, MA 02150
(“Civitas”) and Omega Plastics, Inc., a Michigan corporation with an office at 24401 Capital Blvd, Clinton Township, MI (“Service Provider”). 
  

	1.	Agreement Structure. Omega Plastics is a manufacturing company and provides manufacturing services consistent with injection mold making, injection molding, and assembly of plastic components. From time to
time, Civitas may want Service Provider to provide certain services (other than manufacturing and clinical development-related services) (“Services”). This Agreement contains general terms and conditions under which Civitas would
engage Service Provider and under which Service Provider would provide Services. Civitas and Service Provider must complete and execute a work order, project order or statement of work referencing this Agreement (each, a “Statement of
Work”) before any Services are provided. Each Statement of Work will include, at a minimum, the information relating to the specific Services outlined in the sample Statement of Work attached as Appendix A. However, neither Civitas
nor Service Provider is obligated to accept or execute any Statement of Work. Only after being mutually agreed upon and executed, each Statement of Work becomes part of this Agreement, although the terms in a Statement of Work will apply only to
Services described in that Statement of Work. A Statement of Work may not change any term in this Agreement unless mutually agreed upon. 

  

	2.	About Services. 

  

	 	2.1.	Provision of Services. Service Provider agrees to provide all Services identified in any Statement of Work: (a) within the time period specified in the relevant Statement of Work; and (b) in
accordance with the highest prevailing industry standards and practices for the performance of similar services. For each Statement of Work, Service Provider will designate a “Project Leader” who will be available for frequent
communications with Civitas regarding Services provided under that Statement of Work, as well as contacts for administrative and payment matters for those Services. Civitas will designate a “Civitas Representative” who will be the
point of contact for the Project Leader. 

  

	 	2.2.	Change Orders. If either party identifies a need to modify a Statement of Work, the identifying party will notify the other party in writing as soon as reasonably possible. Service Provider will use
reasonable efforts to provide to Civitas within ten (10) business days after receiving or providing the notice described above a written change order containing a description of the required modifications and their effect on the scope, fees and
timelines specified in the Statement of Work (each, a “Change Order”). No Change Order will be effective unless and until it has been signed by an authorized representative of each party. If Civitas does not approve a Change Order
and has not terminated the Statement of Work, but still desires that the Statement of Work be modified, then the parties will use reasonable good faith efforts to agree on a Change Order that is mutually acceptable. Service Provider will continue to
work under the existing Statement of Work during any such negotiations, to the extent such efforts are practicable and would facilitate the completion of the work envisioned in the Statement of Work, but will not commence work in accordance with the
Change Order until it is authorized in writing by Civitas. 

  
 Confidential 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	2.3.	Subcontracting. With Civitas’ prior written consent, Service Provider may subcontract the performance of specific obligations of Service Provider under a Statement of Work to an Affiliate (as defined
below in this Section 2.3) of Service Provider or to a qualified non-Affiliate third party including, but not limited to, consultants; provided, that (a) such Affiliate or third party performs those Services in a manner consistent
with the terms and conditions of this Agreement; and (b) Service Provider remains liable for the performance of such Affiliate or third party. “Affiliate” means, with respect to either Civitas or Service Provider, any
corporation, company, partnership, joint venture and/or firm which controls, is controlled by or is under common control with Civitas or Service Provider, as applicable. As used in this Section 2.3, “control” means (i) in
the case of corporate entities, direct or indirect ownership of more than percent (50%) of the stock or shares having the right to vote for the election of directors (or such lesser percentage that is the maximum allowed to be owned by a
foreign corporation in a particular jurisdiction); and (ii) in the case of non-corporate entities, the direct or indirect power to manage, direct or cause the direction of the management and policies of the non-corporate entity or the power to
elect more than fifty percent (50%) of the members of the governing body of such non-corporate entity. 

  

	 	2.4.	Regulatory Contacts. Civitas will be solely responsible for all contacts and communications with any regulatory authorities with respect to matters relating to Services. Unless required by applicable law,
Service Provider will have no contact or communication with any regulatory authority regarding Services without the prior written consent of Civitas, which consent will not be unreasonably withheld. Service Provider will notify Civitas promptly, and
in no event later than one (1) business day, after Service Provider receives any contact or communication from any regulatory authority relating in any way to Services and will provide Civitas with copies of any such communication within one
(1) business day after Service Provider’s receipt of such communication. Unless prohibited by applicable law, Service Provider will consult with Civitas regarding the response to any inquiry or observation from any regulatory authority
relating in any way to Services and will allow Civitas at its discretion to control and/or participate in any further contacts or communications relating to Services. Service Provider will comply with all reasonable requests and comments by Civitas
with respect to all contacts and communications with any regulatory authority relating to Services provided to Civitas. 

  

	 	2.5.	Audits. With reasonable notice by Civitas to Service Provider and during normal business hours, Service Provider will allow Civitas employees and representatives and representatives of regulatory
authorities to review Service Provider’s standard operating procedures and records, pertaining to Services and to inspect the facilities used to render Services. In addition, the Project Leader and Civitas Representative and their designees
will participate in meetings to review performance of Services and to coordinate Services as necessary. The Civitas Representative, or his or her designee, will also have access at reasonable times to observe Services in progress or review any and
all Records (as defined in Section 5.4). 

  

	3.	Representations and Warranties of Service Provider. Service Provider represents and warrants as follows: 

  

	 	3.1.	Organization of Service Provider. Service Provider is and will remain a corporation or company duly organized, validly existing and in good standing under the laws of its jurisdiction of organization.

  

	 	3.2.	 Enforceability of this Agreement. The execution and delivery of this Agreement by Service Provider has been authorized by all requisite
corporate or company action. This Agreement is and 

  
 Confidential 

2 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	
will remain a valid and binding obligation of Service Provider for two years, enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency
and the relief of debtors. After two years, this Agreement can be revised or extended as mutually agreed upon. 

  

	 	3.3.	Absence of Other Contractual Restrictions. Service Provider is under no contractual or other obligation or restriction that is inconsistent with Service Provider’s execution or performance of this
Agreement. Service Provider will not enter into any agreement, either written or oral, that would knowingly conflict with Service Provider’s responsibilities under this Agreement. 

 

	 	3.4.	Qualifications of Service Provider Personnel. Service Provider has engaged, will engage and will cause its Affiliates involved in rendering Services to engage, employees and permitted subcontractors
including, but not limited to, consultants (collectively, “Service Provider Personnel”) with the proper skill, training and experience to provide Services. Before providing Services, all Service Provider Personnel except employees
must be subject to binding written agreements with Service Provider under which they (a) have confidentiality obligations with regard to Civitas’ Confidential Information (as defined below) that are consistent with the terms of this
Agreement; and (b) assign and effectively vest in Service Provider any and all rights that such personnel might have in the results of their work without any obligation of Civitas to pay any royalties or other consideration lo such Service
Provider Personnel. Service Provider Employees’ confidentiality will be contained in written obligations sufficient for Service Provider to comply with this Agreement. 

 

	 	3.5.	Compliance. Service Provider will perform all Services with requisite care, skill and diligence, in accordance with all applicable laws, rules, regulations, orders and industry standards. In addition,
Service Provider will comply with all Civitas policies and procedures that have been communicated to Service Provider regarding access to and permitted conduct at Civitas’ premises. 

 

	 	3.6.	Absence of Debarment. Service Provider, its Affiliates, Service Provider Personnel and each of their respective officers and directors, as applicable: (a) have not been debarred and are not subject to
a pending debarment, and will not use in any capacity in connection with Services any person who has been debarred or is subject to a pending debarment, pursuant to section 306 of the United States Food, Drug and Cosmetic Act, 21 U.S.C. § 335a;
(b) are not ineligible to participate in any federal and/or state healthcare programs or federal procurement or non-procurement programs (as that term is defined in 42 U.S.C. 1320a-7b(f)); (c) are not disqualified by any government or
regulatory authorities from performing specific services, and are not subject to a pending disqualification proceeding; and (d) have not been convicted of a criminal offense related to the provision of healthcare items or services and are not
subject to any such pending action. Service Provider will notify Civitas immediately if Service Provider, its Affiliates, any Service Provider Personnel, or any of their respective officers or directors, as applicable, is subject to the foregoing,
or if any action, suit, claim, investigation, or proceeding relating to the foregoing is pending, or to the best of Service Provider’s knowledge, is threatened. 

 

	4.	Compensation. As full consideration for Services, Civitas will pay Service Provider the amounts set forth in the applicable Statement of Work in accordance with the payment schedule set forth in such
Statement of Work. Service Provider will invoice Civitas for all amounts due in United States Dollars. All undisputed payments will be made by Civitas within thirty (30) days after its receipt of an invoice and reasonable supporting
documentation for such invoice. 

  

	5.	Proprietary Rights. 

  

	 	5.1.	 Materials. All documentation, information, and biological, chemical or other materials controlled by Civitas and furnished to Service
Provider by or on behalf of Civitas (collectively, with all 

  
 Confidential 

3 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	
associated intellectual property rights, the “Materials”) will remain the exclusive property of Civitas. Service Provider will use Materials only as necessary to perform
Services. Service Provider will not analyze Materials except as necessary to safely perform Services and will not transfer or make the Materials available to third parties without the prior written consent of Civitas. Service Provider can refuse a
Material(s) should Service Provider be unable to properly handle and manage that Material(s). 

  

	 	5.2.	Deliverables. 

  

	 	(a)	Ownership. Civitas will own all rights throughout the world to all inventions, discoveries, improvements, ideas, processes, formulations, products, computer programs, works of authorship, databases, trade
secrets, know-how, information, data, documentation, reports, research, creations and all other products and/or materials arising from or made in the performance of Services (whether or not patentable or subject to copyright or trade secret
protection) (collectively, with all associated intellectual property rights, the “Deliverables”). Service Provider will assign and does assign to Civitas all right, title and interest in and to all Deliverables and will promptly
disclose to Civitas all Deliverables. For purposes of the copyright laws of the United States, Deliverables constitute “works made for hire,” except to the extent such Deliverables cannot by law be “works made for hire”.

  

	 	(b)	Cooperation. During and after the term, Service Provider will, and will cause its Affiliates and Service Provider Personnel to, (i) cooperate fully in obtaining patent and other proprietary
protection for any patentable or protectable Deliverables, all in the name of Civitas and at Civitas’ cost and expense; and (ii) execute and deliver all requested applications, assignments and other documents, and take such other measures
as Civitas reasonably requests, in order to perfect and enforce Civitas’ rights in the Deliverables. Service Provider appoints Civitas its attorney to execute and deliver any such documents on behalf of Service Provider, its Affiliates, and
Service Provider Personnel in the event Service Provider, its Affiliates, or Service Provider Personnel fail to do so. 

  

	 	(c)	Service Provider Property. Notwithstanding the foregoing, Service Provider will retain full ownership rights in and to all templates, programs, methodologies, processes, technologies and other
materials developed or licensed by Service Provider and its Affiliates prior to or apart from performing its obligations under this Agreement (collectively, with all associated intellectual property rights, the “Service Provider
Property”), regardless of whether such Service Provider Property is used in connection with Service Provider’s performance of its obligations under this Agreement. Service Provider will grant and does grant to Civitas a non-exclusive,
fully paid-up worldwide, sublicensable license to use Service Provider Property as required for Civitas to use the Deliverables; this license will be reviewed every two years for renewal which is to be mutually agreed upon. 

 

	 	5.3.	Work at Third Party Facilities. Service Provider agrees not to accept or use any funds, space, personnel, facilities, equipment or other resources of a third party in performing Services or take any other
action that could result in a third party owning or having a right in any Deliverables. 

  

	 	5.4.	Records; Records Storage. Service Provider will maintain all materials, data and documentation obtained or generated by Service Provider in the course of preparing for and providing Services, including
computerized records and files (collectively, the “Records”) in a secure area reasonably protected from fire, theft and destruction. All Records will be the property of Civitas. Service Provider will not transfer, deliver or
otherwise provide any Records to any party other than Civitas, without the prior written approval of Civitas. 

  
 Confidential 

4 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	5.5.	Record Retention. All Records will be retained by Service Provider for a minimum period of five (5) years following completion of the applicable Statement of Work, or longer if required by applicable
law or regulation. Service Provider will, at the direction and written request of Civitas, promptly deliver Records to Civitas or its designee, or dispose of the Records, unless the Records are required to be retained by Service Provider by
applicable law or regulation or for insurance purposes. In no event will Service Provider dispose of any Records without first giving Civitas sixty (60) days’ prior written notice of its intent to do so. 

 

	6.	Confidential Information. 

  

	 	6.1.	Definition. “Confidential Information” means any and all non-public scientific, technical, financial or business information, or data in whatever form (written, oral or visual) that is
(a) furnished or made available by one party (the “Discloser”) to the other (the “Recipient”) or developed by Service Provider in connection with Services. Confidential Information of Civitas includes, but is
not limited to (x) Materials, Deliverables and Records; (y) development and marketing plans, regulatory and business strategies, financial information, and forecasts of Civitas; and (z) all information of third parties that Civitas
has an obligation to keep confidential and that obligation has been effectively communicated to Service Provider whether or not, in each case, such materials or information are marked or identified as confidential. 

 

	 	6.2.	Obligations. During the term of this Agreement and for a period of ten (10) years thereafter, Recipient agrees to (a) hold in confidence all Discloser’s Confidential Information, and not
disclose Discloser’s Confidential Information except as expressly provided in Section 6.3, without the prior written consent of Discloser, (b) use Discloser’s Confidential Information solely to carry out Recipient’s rights
or obligations under this Agreement; (c) treat Discloser’s Confidential Information with the same degree of care Recipient uses to protect Recipient’s own confidential information but in no event with less than a reasonable degree of
care; and (d) reproduce Discloser’s Confidential Information solely to the extent necessary to carry out Recipient’s rights or obligations under this Agreement, with all such reproductions being considered Discloser’s
Confidential Information. 

  

	 	6.3.	Permitted Disclosures. Recipient may provide Discloser’s Confidential Information solely to its employees or contractors (but if Recipient is Service Provider, then solely to Service Provider
Personnel who are in compliance with Section 3.4) on a need-to-know basis and solely as necessary to carry out Recipient’s rights or obligations under this Agreement; provided, that Recipient remains liable for the compliance of
such employees or contractors (or if Service Provider is Recipient, the compliance of such Service Provider Personnel) with the terms of this Agreement. 

  

	 	6.4.	Exceptions. Recipient’s obligations of non-disclosure and non-use under this Agreement will not apply to any portion of Discloser’s Confidential Information that Recipient can demonstrate, by
competent proof: 

  

	 	(a)	is known to the public at the time of disclosure or becomes generally known through no wrongful act on the part of Recipient; 

  

	 	(b)	is in Recipient’s possession at the time of disclosure other than as a result of Recipient’s breach of any legal obligation; 

 

	 	(c)	becomes known to Recipient on a non-confidential basis through disclosure by sources other than Discloser having the legal right to disclose such Confidential Information; or 

 

	 	(d)	is independently developed by Recipient without reference to or reliance upon Discloser’s Confidential Information. 

  
 Confidential 

5 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 If Recipient is required by a governmental authority or by order of a court of competent
jurisdiction to disclose any Confidential Information, Recipient will give Discloser prompt written notice of such requirement or order and Recipient will take all reasonable and lawful actions to avoid or minimize the degree of such disclosure.
Recipient will cooperate reasonably with Discloser in any efforts to seek a protective order. 
  

	7.	Indemnification, Insurance and Remedies. 

  

	 	7.1.	Indemnification by Service Provider. Service Provider will indemnify, defend and hold harmless Civitas, its officers, directors, employees and agents (collectively, the “Civitas
Indemnitees”) against any third party claims, including reasonable attorneys’ fees for defending those claims, to the extent such claims arise out of or relate to (a) Service Provider’s negligence or willful misconduct in the
performance of Services (except to the extent such claims result from Civitas’ breach of this Agreement or a Civitas Indemnitee’s negligence or willful misconduct); or (b) Service Provider’s breach of this Agreement.

  

	 	7.2.	Indemnification by Civitas. Civitas will indemnify, defend and hold harmless Service Provider, its Affiliates, and its and their respective officers, directors, employees and agents (collectively, the
“Service Provider Indemnitees”) against any third party claims, including reasonable attorneys’ fees for defending those claims, to the extent such claims arise out of or relate to (a) the use of the Deliverables by
Civitas (except to the extent such claims result from Service Provider’s breach of this Agreement or a Service Provider Indemnitee’s negligence or willful misconduct); (b) any Civitas Indemnitee’s negligence or willful misconduct
in performing obligations under this Agreement; or (c) Civitas’ breach of this Agreement; (d) Civitas’ performance of its obligations under this Agreement (except to the extent such claims result from Service Provider’s
breach of this Agreement or a Service Provider Indemnitee’s negligence or willful misconduct). 

  

	 	7.3.	Indemnification Procedures. Each party must notify the other party within thirty (30) days after receipt of any claims made for which the other party might be liable under Section 7.1 or 7.2, as
applicable. The indemnifying party will have the sole right to defend, negotiate, and settle such claims. The indemnified party will be entitled to participate in the defense of such matter and to employ counsel at its expense to assist in such
defense; provided, however, that the indemnifying party will have final decision-making authority regarding all aspects of the defense of the claim. The indemnified party will provide the indemnifying party with such information and
assistance as the indemnifying party may reasonably request, at the expense of the indemnifying party. Neither party will be responsible or bound by any settlement of any claim or suit made without its prior written consent; provided,
however, that the indemnified party will not unreasonably withhold or delay such consent, 

  

	 	7.4.	Insurance. Service Provider will carry, with financially sound and reputable insurers, insurance coverage (including but not limited to, worker’s compensation at or above the applicable statutory
limits, comprehensive liability coverage with contractual liability, and professional liability/errors and omissions coverage) with respect to the conduct of its business against loss from such risks and in such amounts as is customary for
well-insured companies engaged in similar businesses and sufficient to support its obligations under this Agreement, Upon the request of Civitas, Service Provider will provide Civitas with a Certificate of Insurance evidencing such coverage, and
providing that thirty (30) days advance written notice will be given to Civitas of any material change or cancellation in coverage or limits, 

  
 Confidential 

6 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	7.5.	Remedies. In the event that any Services do not meet the specifications or other performance criteria agreed to by Service Provider and Civitas in writing, then the parties will have discussions and allow
for reasonable efforts of Service Provider to correct the Services or devise a plan to correct the Services. If the parties cannot correct the Services under a timeframe reasonably acceptable to Civitas, then Service Provider will, at Civitass
option, promptly (a) re-perform such Services at Service Provider’s cost; or refund to Civitas all service fees paid by Civitas to Service Provider in connection with the specific failed service listed on the Statement of Work and
excluding all successfully completed services that may be listed on the Statement of Work. 

  

	8.	Expiration and Termination. 

  

	 	8.1.	Expiration. This Agreement will expire on the later of (a) two (2) years from the Effective Date or (b) the completion of all Services under all Statement(s) of Work executed by the parties
prior to the second anniversary of the Effective Date. This Agreement may be extended by mutual agreement of the parties or earlier terminated in accordance with Section 8.2 or 8.3. 

 

	 	8.2.	Termination by Civitas. In the event of a breach of this Agreement by Service Provider which cannot be cured (e.g., breach of confidentiality obligations under Section 6), Civitas may terminate
this Agreement or any Statement of Work with immediate effect, at any time upon written notice to Service Provider. Further, Civitas may terminate this Agreement or a Statement of Work at any time upon thirty (30) days’ prior written
notice to Service Provider. 

  

	 	8.3.	Termination by Service Provider. In the event of a breach of this Agreement or of a Statement of Work by Civitas which cannot be cured (e.g., breach of confidentiality obligations under
Section 6), Service Provider may terminate this Agreement or Statement of Work with immediate effect, at any time upon written notice to Civitas. 

  

	 	8.4.	Effect of Termination or Expiration. Upon termination or expiration of this Agreement, neither Service Provider nor Civitas will have any further obligations under this Agreement, or in the case of
termination or expiration of a Statement of Work, under that Statement of Work, except that: 

  

	 	(a)	Service Provider will terminate all affected Services in progress in an orderly manner as soon as practical and in accordance with a schedule agreed to by Civitas, unless Civitas specifies in the notice of termination
that Services in progress should be completed; 

  

	 	(b)	Service Provider will deliver to Civitas or, at Civitas’ option, dispose of, any Materials in its possession or control and all Deliverables developed through termination or expiration; 

 

	 	(c)	Civitas will pay Service Provider any monies due and owing Service Provider, up to the time of termination or expiration, for Services properly performed and all authorized expenses actually incurred (as specified in
the applicable Statement of Work) which includes costs incurred for items related to providing Services, including but not limited to storage, shipping and other costs incurred on behalf of Civitas. 

 

	 	(d)	Service Provider will promptly refund any monies paid in advance by Civitas for Services not rendered; 

  

	 	(e)	each Recipient will promptly return to the Discloser all of Discloser’s Confidential Information (including all copies) provided to Recipient under this Agreement or under any Statement of Work which has been
terminated or has expired, except for one (1) copy which Recipient may retain solely to monitor Recipient’s surviving obligations of confidentiality and non-use, and in the case of Civitas, to exercise all surviving rights of Civitas under
this Agreement; and 

  

	 	(f)	the terms and conditions under Sections 2.3(b), 2.4, 2.5, 3, 5, 6, 7, 8.4 and 9 will survive any such termination or expiration. 

  
 Confidential 

7 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	9.	Miscellaneous. 

  

	 	9.1.	Independent Contractor. Service Provider is an independent contractor and not an agent or employee of Civitas, Service Provider will not in any way represent itself to be an agent, employee, partner or
joint venturer of or with Civitas, and Service Provider has no authority to obligate or bind Civitas by contract or otherwise. Service Provider has full power and authority to determine the means, manner and method of performance of Services.
Service Provider is responsible for, and will withhold and/or pay, any and all applicable federal, state or local taxes, payroll taxes, workers’ compensation contributions, unemployment insurance contributions, or other payroll deductions from
the compensation of Service Provider’s employees and other Service Provider Personnel and no such employees or other Service Provider Personnel will be entitled to any benefits applicable to or available to employees of Civitas. Service
Provider understands and agrees that it is solely responsible for such matters and that it will indemnify Civitas and hold Civitas harmless from all claims and demands in connection with such matters. 

 

	 	9.2.	Publicity. Except to the extent required by applicable law or regulation or the rules of any stock exchange or listing agency, Service Provider will not make any public statement or release concerning this
Agreement or the transactions contemplated by this Agreement or use Civitas’ name or the name of any Affiliate of Civitas in any form of advertising, promotion or publicity, without obtaining the prior written consent of Civitas.

  

	 	9.3.	Notices. All notices must be in writing and sent to the address for the recipient set forth in this Agreement or at such other address as the recipient may specify in writing under this procedure.
Communications and notices to Civitas will be marked “Attention: Paul Burgess, Head of Intellectual Property”. Communications and notices to Service Provider will be marked “Attention: President”. AH notices must be given
(a) by personal delivery, with receipt acknowledged; or (b) by prepaid certified or registered mail, return receipt requested; or (c) by prepaid recognized express delivery service. Notices will be effective upon receipt or at a later
date stated in the notice. 

  

	 	9.4.	Assignment. Except as expressly provided in Section 2.3, Service Provider may not assign, delegate or transfer its obligations under this Agreement, in whole or in part, without the prior written
consent of Civitas, and any attempted assignment, delegation or transfer by Service Provider without such consent will be void. Civitas may assign, delegate or transfer this Agreement in whole or in part without consent of Service Provider. No
assignment, delegation or transfer will relieve either party of the performance of any accrued obligation that such party may then have under this Agreement. 

  

	 	9.5.	Entire Agreement. This Agreement, including the attached Appendix A and any fully-signed Statements of Work, each of which are incorporated into this Agreement, constitute the entire agreement
between the parties with respect to the specific subject matter of this Agreement and all prior agreements, oral or written, including but not limited to the Confidential Disclosure Agreement dated 7/23/2013 with respect to such subject matter are
superseded. Each party confirms that it is not relying on any representations or warranties of the other party except as specifically set forth in this Agreement. If there is any conflict, discrepancy or inconsistency between the terms of this
Agreement and any Statement of Work, purchase order or other form used by the parties, the terms of this Agreement will control, 

  
 Confidential 

8 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	9.6.	No Modification. This Agreement (including Statement(s) of Work) may be changed only by a writing signed by authorized representatives of each party. 

 

	 	9.7.	Severability; Reformation. Each provision in this Agreement is independent and severable from the others, and no provision will be rendered unenforceable because any other provision is found by a proper
authority to be invalid or unenforceable in whole or in part. If any provision of this Agreement is found by such an authority to be invalid or unenforceable in whole or in part, such provision will be changed and interpreted so as to best
accomplish the objectives of such unenforceable or invalid provision and the intent of the parties, within the limits of applicable law. 

  

	 	9.8.	Governing Law. This Agreement and any disputes arising out of or relating to this Agreement will be governed by, construed and interpreted in accordance with the internal laws of the Commonwealth of
Massachusetts without regard to any choice of law principle that would require the application of the law of another jurisdiction. The parties expressly reject any application to this Agreement of (a) the United Nations Convention on Contracts
for the International Sale of Goods; and (b) the 1974 Convention on the Limitation Period in the International Sale of Goods, as amended by that certain Protocol, done at Vienna on April 11, 1980. 

 

	 	9.9.	Waivers. Any delay in enforcing a party’s rights under this Agreement, or any waiver as to a particular default or other matter, will not constitute a waiver of such party’s rights to the future
enforcement of its rights under this Agreement, except with respect to an express written waiver relating to a particular matter for a particular period of time signed by an authorized representative of the waiving party, as applicable.

  

	 	9.10.	No Strict Construction; Headings. This Agreement has been prepared jointly and will not be strictly construed against either party. The section headings are included solely for convenience of reference and
will not control or affect the meaning or interpretation of any of the provisions of this Agreement. 

  

	 	9.11.	Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed to be an original and all of which together will constitute one and the same instrument.

 IN WITNESS WHEREOF, each party has caused this Agreement to be executed by its duly authorized representative as of the Effective
Date. 
  

									
	CIVITAS THERAPEUTICS, INC.	 		 	OMEGA PLASTICS, INC.
					
	By:	 	 /s/ Rick Batycky
	 		 	By:	 	 /s/ Jeff Kaczperski

					
	Print Name:	 	 Rick Batycky
	 		 	Print Name:	 	 Jeff Kaczperski

					
	Title:	 	 CSO
	 		 	Title:	 	 President

  
 Confidential 

9 

 Exhibit 10.13 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS
BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 APPENDIX A 

THIS STATEMENT OF WORK (the “Statement of Work”) by and between Civitas Therapeutics, Inc. (“Civitas”) and Omega Plastics
Inc. (“Service Provider”), will be effective as of the last date of signature below, and upon execution will be incorporated into the Master Contract Services Agreement between Civitas and Service Provider dated 26 September
2013 (the “Agreement”). Capitalized terms used in this Statement of Work will have the same meaning as set forth in the Agreement. 

Civitas hereby engages Service Provider to provide Services, as follows: 
  

	1.	Services. Service Provider will provide the following Services to Civitas: 

 Mold validation costs for
each mold 
 Mold validations activities include a [***] hour IQ run with a full FAI and [***] piece capability study, an OQ-Low and OQ High which each
including a [***] hour run and a [***] piece capability study, and [***] hour PQ runs which includes a [***] piece capability study for each of these runs ([***]), and a validation summary report. The costs below also reflect the preliminary mold
run prior to the IQ. 
  

									
	 	  	Mold Validations	 
	 [***]
	  	 	[***	] 	 	 	[***	] 
	 [***]
	  	 	[***	] 	 	 	[***	] 
	 [***]
	  	 	[***	] 	 	 	[***	] 
	 [***]
	  	 	[***	] 	 	 	[***	] 
	 [***]
	  	 	[***	] 	 	 	[***	] 
	 [***]
	  	 	[***	] 	 	 	[***	] 
	 [***]
	  	 	[***	] 	 	 	[***	] 
	 [***]
	  	 	[***	] 	 	 	[***	] 
		  				 	  
	  
	 
	 Total Validation Cost
	   
	 	 	[***	] 
		  				 	  
	  
	 

 Components and inhalers produced during validation activities belong to Civitas. If the need arises to mold additional
components or to assemble these components during validations activities (i.e. for limited quantity engineering builds) then Civitas will be charged only for the additional components and/or assembly. 

Gage R&R costs for each molded component in-process inspection 

A Gage R&R study will be conducted on all in-process inspection equipment/methods. The pricing below is considered tentative pending 1) receipt and review
of the fixtures being provided by Civitas and 2) review of the latest prints for inspection requirements. 
  

					
	 	  	Gage R&R costs	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
		  	  
	  
	 
	 Total
	  	 	[***	] 
		  	  
	  
	 

  
 Confidential 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Assembly line qualification and validation support costs 

The qualification activity of the assembly line will include IQ and OQ activities, a PQ which includes [***] separate lots of product run mimicking production
runs as much as possible, and a validation summary report. The cost shown below also includes the creation of the Master Validation Plan for the overall system associated with this project. 

 

					
	 	  	Assembly line
qualification	 
	 Assy, calibration, IQ/OQ/PQ, reports
	  	 	[***	] 

 Components and inhalers produced during validation activities belong to Civitas. If the need arises to mold additional
components or to assemble these components during validations activities (i.e. for limited quantity engineering builds) then Civitas will be charged only for the additional components and/or assembly. 

Tooling budget: new tool and engineering changes 

General Notes: 
  

	 	a.	Tooling quotes do not include spares. 

  

	 	b.	Tool debug based on latest tool reviews and current understanding of steel safe conditions. 

  

	 	c.	Preliminary qualification activity includes extended run times (and resin) during initial trial runs, mini-capability study(s), and partial FAI(s). 

 

					
	 Tooling w/ debug + prelim qualification activity

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  		  	[***]
	 NOTES:
	  	

					
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	[***]	  	[***]	  	

  
 Confidential 

2 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 2. Optional Services. Service Provider will provide the following Services to Civitas at the prices
described herein upon the written request of Civitas. The listed prices are based on the number of items per volume order and per the notes associated with the prices. These prices are commitments on behalf of Service Provider to complete the
services in accordance with the requirement of the contract and these prices but with Civitas’s understanding that prices may change per the notes associated with those prices. Any changes in pricing due to a change in requirements or per the
notes associated with the part pricing will be submitted to Civitas in writing. 
 Engineering build assembly part pricing at requested volumes 

 

																					
	 	  	 	 	 	Assembly Pricing: Engineering builds	 
		  				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 CVT-301
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	 	1.	Quoted part pricing is based on information provided in RFP from Civitas and Radius. Pricing is tentative pending confirmation of this information (i.e. cycle times, part weight, etc.) after tools and assembly
equipment has been tested. 

  

	 	2.	Quoted with Tines, Springs (2x) and Capsules supplied by Civitas. 

  

	 	3.	Price reflects the current method of loading the tines. 

  

	 	4.	Part identification/labeling may impact part pricing; to be reviewed once final process is defined. 

  

	 	5.	Smaller lot quantities can be provided and will be quoted as needed. 

  

	 	6.	Assembly pricing quoted with checking fixtures and sonic horns provided by Civitas. If new or revised fixtures and/or sonic horns are needed, these will be quoted in the future (upon receipt of final prints and specs).

 Production build assembly part pricing at requested volumes 

 

																	
	 	  	 	 	 	Assembly Pricing: Production	 
		  				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 Revised CVT-301
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

  

	 	1.	Quoted part pricing is based on information provided in RFP from Civitas and Radius. Pricing is tentative pending confirmation of this information (i.e. cycle times, part weight, etc.) after tools and assembly
equipment has been tested. 

  

	 	2.	Quoted with Tines, Springs (2x) and Capsules supplied by Civitas. 

  

	 	3.	Price reflects the current method of loading the tines. 

  

	 	4.	Part identification/labeling may impact part pricing; to be reviewed once final process is defined. 

  

	 	5.	Smaller lot quantities can be provided and will be quoted as needed. 

  

	 	6.	Assembly pricing quoted with checking fixtures and sonic horns provided by Civitas. If new or revised fixtures and/or sonic horns are needed, these will be quoted in the future (upon receipt of final prints and specs).

 Estimated tray cost for the insert molded Plunger 

Trays to protect the tine sharpness are required. PLEASE NOTE that the pricing below is for custom trays. A suitable “off the shelf” tray was
not found within the timeframe of this RFP. An “off the shelf” tray can be further investigated with the expectation of finding a less expensive tray that can be used in a clean room setting. 

  
 Confidential 

3 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

											
	 	  	 	  	Custom Trays for	 
		  		  	 	Proto and Production Tooling	  	 	 	[***	] 
				
		  		  	 	[***]                     [***	] 	 	 	[***	] 
		  		  	 	[***	] 	 	 	[***	] 
		  		  	 	[***	] 	 	 	[***	] 
		  		  	 	[***	] 	 	 	[***	] 

 3. Timeline. The timeline for completion of the activities is described in the Proposal entitled “Proposal
for the Civitas CVT-301 Dry Powder Inhaler” Revision 3, dated December 2, 2013 and attached herein (the “Proposal”). The optional Compressed Delivery described in Section 9 of the Proposal requires the prior written approval
of Civitas. 
 4. Ownership. All data, molds, products, parts and inhalers shall be the property of Civitas Therapeutics. 

5. Service Provider Contacts. 

Project Leader: Matt Bouey, Program Manager 

Administration Contact: Michael Pavlica, VP 

Payment Contact: Lisa Diller, Accountant 
 6.
Civitas Representative. Sean Plunkett 
 7. Quality Agreement. All Services shall be in compliance with the Quality Agreement
between the parties. 
 8. Compensation. Payment shall be made as described below for each applicable task. 

Engineering build assembly and production build assembly parts (quote sections 2 & 3): Net 30 days from invoice date. Invoicing to occur
upon shipment. 
 Mold Validation (quote section 4): [***] % with FAI, [***] % with completion of PQ runs, [***] % with submission of
validation summary report. Net 30 days from receipt of invoice. 
 Gage R&R Costs (quote section 5): Net 30 days from submission of Gage
R&R study. 
 Assembly line qualification and validation support costs (quote section 6): [***] % with OQ parts, [***] % with PQ parts,
[***] % with submission of validation summary report. Net 30 days from receipt of invoice. 
 Tooling (quote section 10): [***] % down
payment with approved contract/PO, [***] % upon first samples, [***] % upon approval of samples by Civitas. Net 30 day terms from receipt of invoice for sample submission and sample approval. 

9. All terms and conditions of the Agreement will apply to this Statement of Work. In the event of any conflict between this Statement of Work and the
terms of the Agreement, the terms of the Agreement will control. 

  
 Confidential 

4 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 STATEMENT OF WORK AGREED TO AND ACCEPTED BY: 

 

									
	CIVITAS THERAPEUTICS, INC.	 		 	OMEGA PLASTICS, INC.
					
	By:	 	 /s/ Rick Batycky
	 		 	By:	 	 /s/ Jeff Kaczperski

					
	Print Name:	 	 Rick Batycky
	 		 	Print Name:	 	 Jeff Kaczperski

					
	Title:	 	 CSO
	 		 	Title:	 	 President

					
	Date:	 	 January 7, 2014
	 		 	Date:	 	 January 4, 2014

  
 Confidential 

5EX-10.14

 Exhibit 10.14 

Execution Copy 

AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT 

This AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), made as of this 12th day of September
2014, is entered into by Civitas Therapeutics, Inc., a Delaware corporation with its principal place of business at 190 Everett Avenue Chelsea, MA 02150 (the “Company”), and Mark Iwicki, residing at [—] (the “Executive”). 
 WHEREAS, the Company and the Executive entered into
that certain Executive Employment Agreement, dated as of January 12, 2014 (the “Original Agreement”); 
 WHEREAS, the
Company has filed a Form S-1 registration statement under the Securities Act of 1933 with the Securities Exchange Commission and anticipates effecting an initial public offering of the Company’s common stock (the “IPO”); 

WHEREAS, in connection with the anticipated IPO, the Company and the Executive deem it advisable and appropriate to amend and restate the
Original Agreement on the terms set forth herein; and 
 WHEREAS, this Agreement shall become effective immediately prior to the effective
date of the IPO (the “Effective Date”) and, upon its effectiveness, the Original Agreement shall be of no further force or effect, and in the event the IPO does not occur by March 31, 2015, this Agreement shall be void ab
initio and the Company and the Executive shall continue to be bound by the terms of the Original Agreement. 
 In consideration of the
mutual covenants and promises contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties to this Agreement, the parties agree as follows: 

1. Employment/Duties. During the Employment Period (as defined below), the Executive shall serve as President and Chief Executive
Officer of the Company and shall have all the duties, responsibilities and authority commensurate with such position and such additional duties as may be determined by the Company’s Board of Directors (“Board of Directors”).
The Executive shall be based at the Company’s principal place of business in the greater Boston, Massachusetts metropolitan area, or such place or places in the continental United States as the Board of Directors shall determine. The Executive
shall report to, and be subject to the general supervision of, the Board of Directors. 
 The Executive agrees to devote substantially all
of his business time, attention and energies to the business and interests of the Company during the Employment Period; provided, however, that the Executive may be permitted to engage in other activities, including membership on
boards of directors of other businesses or non-for-profit organizations, so long as such activities do not materially interfere with the performance of the Executive’s duties under this Agreement and have been disclosed to and approved in
advance by the Board of Directors. The Executive’s service as a member on the board of directors of Blend Therapeutics, Inc. and Wellesley Youth Hockey shall be deemed to have been disclosed and approved by the Board of

 
Directors. The Executive agrees to abide by the rules, regulations, personnel practices and policies of the Company, as adopted and amended from time to time by the Company, provided, that
such rules, regulations, practices and policies are not inconsistent with the terms and conditions of this Agreement and have been disclosed to the Executive. 

Further, during the Employment Period, subject to the requirements of applicable law (including, without limitation, any rules or regulations
of any exchange on which the common stock of the Company is listed, if applicable), the Company agrees to propose to the shareholders of the Company at each annual meeting occurring during the Employment Period at which the class of directors of
which the Executive is a part is subject to election or re-election, as applicable, the election or re-election, as applicable, of the Executive as a member of the Board of Directors and the Executive shall so serve if elected or re-elected;
provided, however, that if the Executive’s employment with the Company terminates for any reason, the Executive’s membership on the Board shall also terminate, unless otherwise agreed in writing by the Company and the
Executive. 
 2. Effective Date/Period of Employment. Executive’s employment with the Company commenced on January 27, 2014
(the “Original Effective Date”). Employment under this Agreement will become effective on the Effective Date and shall continue until terminated in accordance with the provisions of Section 4 (the “Employment
Period”), subject to Section 9.13. 
 3. Compensation and Benefits. 

3.1. Base Salary. During the Employment Period, the Company shall pay the Executive a base salary of $460,000.00 calculated on an
annual basis (as increased, “Base Salary”), paid in periodic installments in accordance with the Company’s customary payroll practices. The Base Salary shall be reviewed for increase no less frequently than annually, beginning
at the end of calendar year 2014. 
 3.2. Additional Compensation. 

(a) Annual Bonus Opportunity. During the Employment Period, the Executive may be eligible to receive an annual cash bonus no later than
sixty (60) days after the end of each calendar year, as determined by the Board of Directors (or its Compensation Committee) in its good faith discretion. The bonus (if any) will be awarded based on objective or subjective criteria established
by the Board of Directors (or its Compensation Committee). The Executive’s target bonus will be equal to 55% of the Executive’s Base Salary (the “Annual Bonus”). 

3.3. Equity Compensation. 

(a) Existing Equity Grants. Pursuant to the Original Agreement, the Executive was granted a stock option to purchase 3,476,972 shares
of the Company’s common stock on January 29, 2014 and an additional stock option to purchase 915,242 shares of the Company’s common stock on August 22, 2014 (collectively, the “Existing Options”). The terms and
conditions of the Existing Options are subject to the award agreements executed in connection with the grants of the Existing Options and the Company’s 2010 Stock Incentive Plan. 

  
 -2- 

 (b) Future Equity Grants. The Executive shall be eligible to receive additional equity
grants as determined by the Compensation Committee of the Board of Directors or the Board of Directors. It is understood and agreed that all equity awards granted to the Executive from and after the Effective Date shall be subject to the following
vesting acceleration provisions: (i) upon the consummation of an Acquisition (including a termination without Cause or resignation for Good Reason occurring within two months prior to the consummation of an Acquisition), (A) all of the
Executive’s then-outstanding time-based equity awards shall become immediately vested and, to the extent stock options or stock appreciation rights, exercisable, and (B) with respect to the Executive’s then-outstanding
performance-based equity awards, the Executive shall be deemed to have satisfied the service-based component of such awards as of the date of such Acquisition but such awards, but the treatment of such awards in the event of an Acquisition shall
otherwise be subject to the terms of such awards or the plan under which any such awards were granted, and (ii) in the event the Executive is terminated by the Company without Cause or the Executive Resigns for Good Reason (and (i) above
does not apply), (A) the Executive shall receive twelve (12) months of vesting acceleration on all of the Executive’s then-outstanding time-based equity awards and (B) with respect to the Executive’s then-outstanding
performance-based equity awards, the Executive shall be deemed to have satisfied the service-based component of the portion of such awards that would have vested based on service within twelve (12) months of the date of such termination and the
Executive shall be eligible to vest with respect to the performance-based component of such awards if the performance criteria are satisfied within twelve (12) months of the Executive’s termination of employment. 

3.4. Benefits. During the Employment Period, the Executive shall be entitled to participate in all benefit programs that the Company
makes available to its employees, if any, to the extent that Executive’s position, tenure, health and other qualifications make the Executive eligible to participate. The Executive shall be entitled to take four weeks of paid vacation
consistent with the company’s employee benefits policy in addition to customary business holidays approved by the Board of Directors for the Company’s employees generally. 

3.5. Reimbursement of Expenses. 

(a) The Company shall reimburse the Executive for all reasonable travel, entertainment and other expenses incurred or paid by the Executive in
connection with, or related to, the performance of the Executive’s duties, responsibilities or services on behalf of the Company under this Agreement, in accordance with policies and procedures, and subject to reasonable limitations, adopted by
the Company from time to time. 
 (b) The Company shall reimburse the Executive for the reasonable fees and out-of-pocket expenses of the
Executive’s counsel incurred in connection with the negotiation of the amendment and restatement of the Original Agreement, in an amount not to exceed $10,000. 

3.6. Withholding. All salary, bonus and other compensation payable to the Executive during the Employment Period shall be subject to
applicable required deductions for state and federal withholding tax, social security and all other employment taxes and payroll deductions. 

  
 -3- 

 4. Termination of Employment Period. The employment of the Executive by the Company
pursuant to this Agreement shall terminate upon the occurrence of any of the following: 
 4.1. By the Company for Cause. At the
election of the Company, for Cause, provided that prior to a termination of the Executive’s employment pursuant to subsection (iii), below, the Executive shall have thirty (30) days to cure in all material respects such Cause event(s)
following the Executive’s receipt of written notice by the Company, which notice shall specifically identify the Cause upon which the termination is based and after the Executive has been given such notice. For the purposes of this
Section 4.1, “Cause” means (i) the Executive’s conviction of, or guilty plea to, a felony, (ii) the Executive’s commission of a fraudulent or materially dishonest act in connection with the Executive’s
employment by the Company, or (iii) the Executive’s willful and repeated failure or refusal to attempt to perform the Executive’s duties to the Company or material breach of this Agreement or any other agreement between the Company
and the Executive in each case after written notice to Executive and the failure to cure within twenty (20) days thereafter (unless such act or omission, by its nature, may not be remedied, in which case such determination of Cause may be
effective immediately). The Executive shall be considered to have been discharged for “Cause” if (based on a final, unappealable judicial determination) the Executive has resigned from the Company without Good Reason to avoid a termination
for Cause based on an event that occurred prior to such resignation (but not an event about which the Board of Directors had actual knowledge for more than ninety (90) days prior to such resignation). 

4.2. Death or Disability. Upon the death of Executive or written notice by the Company to Executive of termination for Disability (as
defined below) of the Executive given while the Executive remains Disabled. For purposes of this Section 4.2, “Disability” means (i) the Executive has been incapacitated by mental or physical injury or illness so as to be
prevented thereby from engaging in the performance of the Executive’s duties to the Company and (ii) such incapacity has continued for a period of one hundred twenty (120) consecutive days. 

4.3. By the Executive for Good Reason. At the election of the Executive, for Good Reason, provided that the Company shall have thirty
(30) days to cure in all material respects such Good Reason event(s) following the Company’s receipt of the Executive’s written notice of such Good Reason event(s). For the purposes of this Section 4.3, “Good
Reason” for termination shall mean (i) a reduction in the Executive’s Base Salary, (ii) any material diminution or other adverse change in the Executive’s authority, responsibilities or duties without the prior written
consent of the Executive, (iii) a material breach by the Company of this Agreement or any other material agreement between the Company and the Executive, (iv) the relocation, without the written consent of the Executive, of the place of
business at which the Executive principally performs Executive’s duties hereunder to a location that is greater than 35 miles from place of business at which the Executive principally performs Executive’s duties hereunder immediately prior
to such relocation, or (v) an Acquisition. Notwithstanding the foregoing, (A) the Executive will be deemed to have given consent to the condition(s) described in this Section 4.3 if the Executive does not provide written notice to the
Company of such Good Reason event(s) within ninety (90) days from first occurrence of such Good Reason event(s) and (B) to the extent the Company has not cured such Good Reason event(s) during the 30-day cure period, the Executive must
terminate the Executive’s employment for Good Reason no later than 

  
 -4- 

 
one hundred and eighty (180) days following the occurrence of such Good Reason event(s) by providing the Company thirty (30) days prior written notice of termination, which may run
concurrently with the Company’s cure period. 
 For purposes of this Agreement, an “Acquisition” shall mean (A) any acquisition of the
Company by a Person (as defined below) not an Affiliate (as defined below) of the Company, by means of merger or other form of corporate reorganization in which the outstanding ownership interests of the Company are exchanged for securities or other
consideration issued, or caused to be issued, by the acquiring Person and in which the holders of the Company’s ownership interests hold less than fifty percent (50%) of the acquiring or surviving Person (other than a mere reincorporation
transaction), (B) the closing of the transfer from existing Company stockholder’s, in one transaction or a series of related transactions, to a Person or group of affiliated Persons, of the Company’s securities if, after such closing,
such Person or group of affiliated Persons would hold more than 50% of the outstanding voting securities of the Company or (C) a sale of all or substantially all of the assets of the Company by a Person not an Affiliate of the Company;
provided, however, that an “Acquisition” shall not include an initial public offering of the Company’s stock or a mere recapitalization transaction or the sale of equity by the Company through a private offering of shares to venture
capital, institutional, strategic or other equity security financing for the account of the Company. 
 For purposes of this Agreement, an
“Affiliate” means with respect to a specified Person, any Person that directly or indirectly controls, is controlled by, or is under common control with, the specified Person (as used in this definition, the term “control” means
the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person or entity, whether through ownership of voting securities, by contract or otherwise). 

For purposes of this Agreement, a “Person” shall mean any individual, company, corporation, association, partnership (general or limited), joint
venture, trust, estate, limited liability company or other legal entity or organization. 
 4.4. By the Company Not For Cause or By the
Executive Not For Good Reason. At the election of the Company for reasons other than Cause, or the election of the Executive for reasons other than Good Reason, upon not less than thirty (30) days’ prior written notice of termination.

 5. Effect of Termination. 

5.1. Payments Upon Termination. 

(a) In the event the Executive’s employment is terminated pursuant to Section 4.1, or by the Executive pursuant to Section 4.4,
the Company shall pay to the Executive the “Accrued Benefits,” which shall mean: (i) any earned but unpaid Base Salary pursuant to Section 3.1 through the last day of the Executive’s actual employment by the Company;
(ii) any unreimbursed expenses incurred through the last day of the Executive’s actual employment by the Company and reimbursable under Section 3.5; (iii) all other payments, benefits or fringe benefits to which the Executive
shall be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant or this Agreement; but, 

  
 -5- 

 
for clarity, shall have no obligation to pay any amounts pursuant to Section 3.2; and (iv) in the case of death, Disability termination, without Cause termination or Good Reason
termination, a pro rata bonus paid sixty (60) days after termination based on the target Annual Bonus and the period of the year during which the Executive was employed. 

(b) In the event the Executive’s employment is terminated pursuant to Sections 4.2, 4.3 or by the Company pursuant to Section 4.4,
then the Company shall pay to the Executive: (i) the Accrued Benefits; (ii) any unpaid annual bonus with respect to the calendar year ending on or preceding the date of termination, which shall be payable at the time such bonuses would
have been paid if the Executive was still employed with the Company and in accordance with Section 3.2(a); (iii) the Base Salary pursuant to Section 3.1 as in effect on the date of termination, which amount shall be paid during the
Severance Period (as defined below); (iv) the target Annual Bonus for the fiscal year in which the Executive’s employment is terminated, which aggregate amount shall be payable in equal amounts in accordance with the Company’s
standard payroll procedures over the course of the Severance Period; and (v) reimbursement for COBRA continuation medical benefits for the Executive (and the Executive’s eligible dependents) during the Severance Period. The payments under
subparts (iii), (iv) and (v) shall begin on the sixtieth (60th) day after the date of termination and shall include any amounts due prior to such date. For the avoidance of doubt,
unless otherwise elected by the Board of Directors, in its sole discretion and to the extent permitted under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), to make payments sooner, any payments made
pursuant to this Section 5.1(b) shall be subject to the Company’s standard payroll schedule during the Severance Period. For the purposes of this Section 5.1(b), “Severance Period” means the period beginning on the
date of termination and continuing afterward for twelve (12) months. 
 (c) The payments to be made or benefits to be provided to the
Executive under paragraph (b) above other than Accrued Benefits: (i) shall be contingent upon the execution (and non-revocation) within sixty (60) days following termination of employment by the Executive of a general release of the
Company, its affiliates, stockholders, directors, officers, employees and agents from all claims (other than claims for the payments to be made and benefits to be provided), together with a mutual agreement to not make any disparaging comments,
statements or communications about the Executive, the Company, its affiliates, stockholders, directors, officers, employees or agents, or its management or business practices for three (3) years following termination of the Executive’s
employment, all in substantially the form annexed hereto as Exhibit A; (ii) shall be contingent upon the Executive’s material compliance with all material continuing obligations under the Company’s standard Employee
Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (the “Proprietary Rights Agreement”); and (iii) shall constitute the sole remedy of the Executive in the event of a termination of the Executive’s
employment in the circumstances set forth in Section 5.1(b). 
 5.2. Section 409A. 

(a) Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to the Executive, if any,
pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Code Section 409A, and the final regulations and any

  
 -6- 

 
guidance promulgated thereunder (collectively, the “Deferred Payments”) will be paid or otherwise provided until the Executive has a “separation from service” within
the meaning of Code Section 409A. 
 (b) Notwithstanding anything to the contrary in this Agreement, if the Executive is a
“specified employee” within the meaning of Code Section 409A at the time of the Executive’s termination (other than due to death), then the Deferred Payments that are payable within the first six months following the
Executive’s separation from service, will become payable on the first payroll date that occurs on or after the date six months and one day following the date of the Executive’s separation from service. Notwithstanding anything herein to
the contrary, if the Executive dies following the Employee’s separation from service, but prior to the six-month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump
sum as soon as administratively practicable after the date of the Executive’s death. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury
Regulations. 
 (c) Any amount paid under this Agreement that satisfies the requirements of the “short-term deferral” rule set
forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments. 
 (d) This Agreement is intended to
be exempt from the requirements of Code Section 409A or compliant therewith so that none of the payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein
will be interpreted accordingly. The Company and the Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any
additional tax or income recognition prior to actual payment to the Executive under Section 409A. 
 6. Restrictive Covenants.
During the Executive’s employment with the Company, the Executive will be exposed to, and provided with, valuable confidential and/or trade secret information concerning the Company and its present and future business plans and operations. As a
result, in order to protect the Company’s legitimate business interests, the Executive shall, as a condition of commencing employment, execute and deliver to the Company the Company’s standard Proprietary Rights Agreement, a copy of which
is attached to this Agreement as Exhibit B. For clarity, the obligations and covenants of the Executive pursuant to the Proprietary Rights Agreement constitute material responsibilities of the Executive to the Company pursuant to this
Agreement. 
 7. Other Agreements. The Executive represents that the Executive’s performance of all the terms of this Agreement
and the performance of the Executive’s duties as an employee of the Company do not and will not breach any agreement with any prior employer or other party to which the Executive is a party (including without limitation any nondisclosure or
non- competition agreement), or violate or contravene any judgment, administrative order or other legal prohibition specifically naming the Executive. The Executive agrees that if the Executive, during the Employment Period, becomes subject to any
such agreement or prohibition, the Executive shall immediately notify the Company. The Company acknowledges that it is aware 

  
 -7- 

 
that the Executive may be subject to certain confidentiality and non-disparagement covenants with respect to the Executive’s prior employers. 

8. Indemnification. The Company shall indemnify and hold harmless the Executive against any liability asserted against or incurred by
the Executive in the Executive’s capacity as a director, officer and/or employee of the Company or an affiliate of the Company or as fiduciary of any Company employee benefit plan to the fullest extent permitted by law. Notwithstanding the
foregoing, the Executive shall have no right to indemnification on account of: (a) acts or omissions of the Executive finally adjudged to be intentional misconduct, gross negligence, fraud or a violation of law; or (b) any transaction with
respect to which it is finally adjudged that the Executive personally received a benefit in money, property or services to which the Executive was not legally entitled. In addition, the Company shall include the Executive within the coverage of any
directors and officers liability insurance policy to the full extent that any other director or other executive officer of the Company, as applicable, is so covered. The indemnification and insurance provisions of this paragraph shall survive the
Executive’s termination of employment with the Company and while potential liability exists. 
 9. Miscellaneous. 

9.1. Notices. Any notices delivered under this Agreement shall be deemed duly delivered four (4) business days after it is sent by
registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent for next-business day delivery via a reputable nationwide overnight courier service, in each case to the address of the recipient set forth
in the introductory paragraph of this Agreement. Either party may change the address to which notices are to be delivered by giving notice of such change to the other party in the manner set forth in this Section 9.1. 

9.2. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 
 9.3. Entire
Agreement. This Agreement, together with the Proprietary Rights Agreement and with the stock option agreement and Adoption Agreement contemplated by Section 3.3, constitutes the entire agreement between the parties and supersedes all prior
agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. 
 9.4. Amendment. This
Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive. 
 9.5. Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflicts of laws provisions of the Commonwealth of Massachusetts). 

9.6. Resolution of Disputes. Any dispute, difference or controversy arising under this Agreement, the Proprietary Rights Agreement
and/or the stock option agreement and Adoption Agreement contemplated by Section 3.3 shall be settled by arbitration. Any arbitration pursuant to this Section shall be held before a single neutral arbitrator selected from the roles of

  
 -8- 

 
the American Arbitration Association pursuant to the Commercial Arbitration Rules. The arbitrator (a) shall not have the power or authority to add to, alter, amend or modify the terms of
this Agreement, (b) shall have no power to award punitive or exemplary damages; and (c) shall interpret and construe this Agreement in accordance with, and shall be bound by the laws of the Commonwealth of Massachusetts. Except as
otherwise set forth herein, each party shall bear its own expenses for counsel and other out-of-pocket costs in connection with any resolution of a dispute, difference or controversy. Any arbitration shall take place in Boston, Massachusetts or at
such other location as the parties may agree upon, according to the American Arbitration Association’s Commercial Arbitration Rules now in force and hereafter adopted. The arbitrator shall make any award in accordance with and based upon all
the provisions of this Agreement and judgment upon any award rendered by the arbitrator shall be entered in any court having jurisdiction thereof. The fees and disbursements of such arbitrator shall be borne equally by the parties, with each party
bearing its own expenses for counsel and other out-of-pocket costs. 
 9.7. Successors and Assigns. This Agreement shall be binding
upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s assets or business, provided,
however, that the obligations of the Executive are personal and shall not be assigned by the Executive. The Company may only assign this Agreement to any successor to all or substantially all of the business and/or assets of the Company,
provided that the Company shall secure such successor’s written agreement to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such
succession had taken place. As used in this Agreement, “Company” shall mean the Company and any successor to its business and/or assets, which assumes and agrees to perform the duties and obligations of the Company under this
Agreement by operation of law or otherwise. 
 9.8. Waivers. No delay or omission by the Company or the Executive in exercising any
right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company or the Executive on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of
any right on any other occasion. 
 9.9. No Mitigation; No Offset. In no event shall the Executive be obligated to seek other
employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, nor shall the amount of any payment hereunder be reduced by any compensation earned by the Executive as a
result of employment by a subsequent employer. 
 9.10. Captions. The captions of the sections of this Agreement are for convenience
of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. 
 9.11.
Severability. In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

  
 -9- 

 9.12. Execution; Counterparts. This Agreement may be executed in several counterparts,
each of which shall be deemed to be an original but all of which together will constitute one and the same instrument. This Agreement may be executed and delivered by facsimile, email/pdf format or other electronic means and each party may fully
rely upon such execution and delivery. 
 9.13. Survival. The provisions of Sections 5, 6, 7, 8 and 9 shall survive the termination
of this Agreement. 
 9.14. 280G. 

(a) If any payment or benefit (including payments and benefits pursuant to this Agreement) that Executive would receive in connection with an
Acquisition from the Company or otherwise (“Transaction Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this Section 9.14, be
subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Transaction Payment are paid to Executive, which of the following two
alternative forms of payment would result in Executive’s receipt, on an after-tax basis, of the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject to the Excise Tax:
(1) payment in full of the entire amount of the Transaction Payment (a “Full Payment”), or (2) payment of only a part of the Transaction Payment so that Executive receives the largest payment possible without the
imposition of the Excise Tax (a “Reduced Payment”). 
 For purposes of determining whether to make a Full Payment or a
Reduced Payment, the Company shall cause to be taken into account all applicable federal, state and local income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal
income taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment is made, (x) Executive shall have no rights to any additional payments and/or benefits constituting the Transaction Payment, and
(y) reduction in payments and/or benefits shall occur in the manner that results in the greatest economic benefit to Executive as determined in this paragraph. If more than one method of reduction will result in the same economic benefit, the
portions of the Payment shall be reduced pro rata. 
 (b) The independent registered public accounting firm engaged by the Company as of the
day prior to the effective date of the Acquisition shall make all determinations required to be made under this Section 9.14. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for
the individual, entity or group effecting the Acquisition, the Company shall appoint a nationally recognized independent registered public accounting firm that is reasonably acceptable to Executive (and such acceptance shall not be unreasonably
withheld) to make the determinations required hereunder. The Company shall bear all reasonable expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder. The independent
registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on

  
 -10- 

 
which Executive’s right to a Transaction Payment is triggered or such other time as reasonably requested by the Company or Executive. If the independent registered public accounting firm
determines that no Excise Tax is payable with respect to the Transaction Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with detailed supporting calculations of its determinations
that no Excise Tax will be imposed with respect to such Transaction Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive. 

  
 -11- 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set
forth above. 
  

			
	CIVITAS THERAPEUTICS, INC.
	
	 /s/ Timothy S. Nelson

	By:	 	Timothy S. Nelson
	Its:	 	Chairman, Board of Directors
	
	EXECUTIVE
	
	 /s/ Mark Iwicki

	Name:	 	Mark Iwicki

 Execution Copy 

Exhibit A 
 General Release

 Exhibit 

FORM OF GENERAL RELEASE 

Mark Iwicki (“Employee”), in consideration for receiving the severance benefits described in Section 5.1(b) of that
certain Executive Employment Agreement (the “Employment Agreement”) between Employee and Civitas Therapeutics, Inc. (the “Employer”), does hereby fully release the Employer, including all of its past, present and
future directors, members, officers, stockholders, employees, agents, affiliates and representatives, from any and all claims of every kind and nature whatsoever, known or unknown, either at law or in equity, arising out of or related to his
employment with, service to, or engagement with the Employer and/or termination of employment or pursuant to any federal, state or local laws, regulations, executive orders or other requirements, including but not limited to claims regarding wages
and hours pursuant to the Massachusetts Wage Act, M.G.L. c. 149, §§148, et seq., the Age Discrimination in Employment Act, any claims arising out of any employment agreement entered into by Employee and Employer and any claims of
discrimination based upon race, color, sex, age, religion, national or ethnic origin, sexual orientation, disability, handicap, status as a Vietnam Era Veteran, or any other protected classification; provided, however, that nothing in this release
shall operate to limit or negate Employee’s rights, if any, (i) to indemnification (and advancement of legal fees) by the Company for any acts or omissions taken by Employee in good faith as an officer or director of the Company or as a
fiduciary of any benefit plan of the Company; (ii) to directors’ and officers’ liability insurance; (iii) to any vested equity and any rights set forth in agreements related thereto; or (iv) to post-termination compensation
and benefits to which Employee is entitled under his employment agreement with Employer. 
 Employee represents that he understands the
various claims he could have asserted under M.G.L. c. 151B, M.G.L. c. 149, the American with Disabilities Act, Title VII of the Civil Rights Act of 1964, the Age Discrimination In Employment Act, and other such similar laws; that he has read this
Release carefully and understands all of its provisions; that he understands that he has the right to and is advised to consult an attorney concerning this Release and in particular the waiver of rights he might have under these laws; that to the
extent, if any, that he desired, he has availed himself of this right; that the consideration received by him is above and beyond the payments or benefits otherwise owed to him under the terms of him employment with the Employer or required by law;
that he has, pursuant to the Older Workers Benefit Protection Act, been provided at least twenty-one (21) days to consider whether to sign this Release; and that he enters this Release and waives any claims knowingly and willingly. 

In addition to the foregoing, Employee hereby agrees he is waiving all rights under Paragraph 1542 of the California Civil Code (or any
analogous law of any other state), which reads as follow: 
 “A general release does not extend to claims which the creditor does not
know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” 

 This Release will not affect the rights and responsibilities of the U.S. Equal Employment
Opportunity Commission (“EEOC”) to enforce the ADEA and other laws, but Employee understands that he is knowingly and voluntarily waiving all rights or claims arising prior to his execution of the Release to receive any payment,
benefit or remedial relief as a consequence of any charge filed with the EEOC and/or of any litigation concerning any facts alleged in any such charge. 

Employee acknowledges and agrees that, but for providing this general release, Employee would not be receiving the benefits described in
5.1(b) of the Employment Agreement. 
 Employee agrees that for three (3) years following his termination from the Employer, he will
not make any statements that are disparaging or adverse to the Employer, its affiliates, stockholders holding more than 5% of the Employer’s outstanding capital stock, directors, officers, or employees, or its management or business practices.
Employer agrees that for three (3) years following Employee’s termination, its directors and executive officers will not to make any statements that are disparaging or adverse to the Employee, including any statement that disparages any
skills, work performance, capabilities or other aspect of Employee’s service as an employee of the Employer; provided, that these provisions shall not prohibit any party (A) from disclosing that Employee is no longer employed by the
Employer; (B) from responding truthfully to any governmental investigation, legal process or related inquiry; (C) from making reasonable competitive statements in the course of promoting a competing business, so long as any statements
described in this clause (C) do not violate the Invention, Non-Disclosure, Non-Competition and Non-Solicitation Agreement between the Employee and Employer, dated January     , 2014, or (D) making a good faith
rebuttal of another person’s untrue or misleading statement. 
 This Release will become effective seven (7) days after it is
signed. Employee may revoke this Release within seven (7) days after it is signed, and it will not become effective or enforceable until this seven (7) day revocation period has expired. After the revocation period has expired, this
Release will be forever binding on the Employee. The Employee acknowledges that he may hereafter discover facts not now known to him relating to his hire, employment or termination of employment, and agrees that this Release will remain in effect
notwithstanding any such discovery of any such facts. The Employee will not bring any proceeding to challenge the validity of this Release. 

 IN WITNESS WHEREOF, Mark Iwicki has caused this instrument of GENERAL RELEASE to be executed and
sealed on this     day of             , 20    . 
  

	
	  

	Mark Iwicki

  

	
	Signed and sealed in the presence of:
	
	  

	 Notary Public
 My Commission
expires:

 Execution Copy 

Exhibit B 
 Proprietary
Rights Agreement 

 INVENTION, NON-DISCLOSURE, NON-COMPETITION 

AND NON-SOLICITATION AGREEMENT 

This Agreement (“Agreement”) is made by and between Civitas Therapeutics, Inc., a Delaware corporation (hereinafter referred to
collectively with its subsidiaries as the “Company”), and Mark Iwicki (the “Employee”). 
 In consideration of the
continued employment of the Employee by the Employee agree as follows: 
 1. Condition of Employment. 

The Employee acknowledges that his/her employment and/or the continuance of that employment with the Company, the bonus or other monetary
consideration that the Employee will receive at the commencement of his/her employment and/or in connection with entering into this Agreement, any options, restricted stock, restricted stock units and other stock- based awards granted at any time to
the Employee by the Company, and the Company’s receipt of funding from the Investors are contingent upon his/her agreement to sign and adhere to the provisions of this Agreement. The Employee further acknowledges that his employment will
require the Company share with him proprietary and confidential information of the Company and that the nature of the Company’s business is such that protection of its proprietary and confidential information is critical to the survival and
success of the Company’s business. This Agreement is intended to protect the Company’s proprietary and confidential information and business without unreasonably restricting the Employee’s ability to work elsewhere if his/her
employment with the Company ends. The Employee agrees to be bound by this Agreement in circumstances of both voluntary and involuntary termination of employment, and regardless of whether additional severance compensation is paid by the Company.

 2. Proprietary and Confidential Information. 

(a) The Employee agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning
the Company’s business or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company. By way of illustration, but not limitation, Proprietary Information may include discoveries,
inventions, products, product improvements, product enhancements, processes, methods, techniques, formulas, compositions, compounds, negotiation strategies and positions, projects, developments, plans (including business and marketing plans),
research data, clinical data, financial data (including sales costs, profits, pricing methods), personnel data, computer programs (including software used pursuant to a license agreement), customer, prospect and supplier lists, and contacts at or
knowledge of customers or prospective customers of the Company. The Employee will not disclose any Proprietary Information to any person or entity other than employees of the Company or use the same for any purposes (other than in the performance of
his/her duties as an employee of the Company) without written approval by an officer of the Company, either during or after his/her employment with the Company, unless and until such Proprietary Information has become public knowledge without fault
by the Employee. 

 
While employed by the Company, the Employee will use the Employee’s best efforts to prevent unauthorized publication or disclosure of any of the Company’s Proprietary Information. 

(b) The Employee agrees that all files, documents, letters, memoranda, reports, records, data, sketches, diagrams, drawings, models,
laboratory notebooks, program listings, computer equipment or devices, formulations, manufacturing equipment and layouts, methods, computer programs or other written, electronic, photographic, or other tangible or intangible material containing
Proprietary Information, whether created by the Employee or others, which shall come into his/her custody or possession, shall be and are the exclusive property of the Company to be used by the Employee only in the performance of his/her duties for
the Company and shall not be copied or removed from the Company premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Employee
shall be delivered to the Company, upon the earlier of (i) a request by the Company or (ii) termination of his/her employment. After such delivery, the Employee shall not retain any such materials or copies thereof or any such tangible
property. The foregoing shall not cover contact information in Employee’s address books, which Employee may retain and utilize. 
 (c)
The Employee agrees that his/her obligation not to disclose or to use information and materials of the types set forth in paragraphs 2(a) and 2(b) above, and his/her obligation to return materials and tangible property, set forth in paragraph 2(b)
above, also extends to such types of information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Employee in the
course of the Company’s business. 
 (d) However, in the event that the Employee (i) is required, by court or administrative or
regulatory order, or any governmental regulator with jurisdiction over the Employee, to disclose any portion of the Proprietary Information or (ii) is asked to or seeks to enter into evidence or otherwise voluntarily disclose in any
administrative, judicial, quasi- judicial or arbitral proceeding, any portion of the Proprietary Information, the Employee shall provide the Company with prompt written notice of any such request or requirement prior to the disclosure of Proprietary
Information, so the Company may, at the Company’s expense, seek a protective order or other appropriate remedy to prohibit or to limit such disclosure. If, in the absence of a protective order, the Employee is nonetheless compelled to disclose
any Proprietary Information, the Employee shall as soon as practicable thereafter advise the Company of the Proprietary Information so disclosed and the persons to whom it was so disclosed, and thereafter, may disclose only such portions of the
Proprietary Information that are legally required to be disclosed. 
 3. Developments. 

(a) The Employee will make full and prompt disclosure to the Company of all discoveries, inventions, improvements, enhancements, processes,
methods, techniques, developments, designs, layouts, diagrams, prototypes, formulations, equipment, articles of manufacture, compositions of matter, software, and works of authorship, whether patentable or not, (i) which have been created,
made, conceived or reduced to practice by the Employee or under his/her direction or jointly with others prior to the date hereof and which relate directly or 

  
 -2- 

 
indirectly to the Company’s proposed business, products or research and development, (ii) which are created, made, conceived or reduced to practice by him/her or under his/her direction
or jointly with others during his/her employment by the Company, whether or not during normal working hours or on the premises of the Company, or (iii) which are created, made, conceived or reduced to practice by him/her or under his/her
direction or jointly with others using the Company’s tools, devices, equipment or Proprietary Information (all of which are collectively referred to in this Agreement as “Developments”). 

(b) The Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all his/her right,
title and interest in and to all Developments and all related patents, patent applications, copyrights and copyright applications and other intellectual property rights therein. However, this paragraph 3(b) shall not apply to Developments (described
in clauses 3(a)(ii) and 3(a)(iii) above) which do not relate to the business or research and development conducted or planned to be conducted by the Company at the time such Development is created, made, conceived or reduced to practice and which
are made and conceived by the Employee outside of normal working hours, off of the Company’s premises and without using the Company’s tools, devices, equipment or Proprietary Information. The Employee understands that, to the extent this
Agreement shall be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this paragraph 3(b) shall be interpreted not to apply to any
invention which a court rules and/or the Company agrees falls within such classes. The Employee also hereby waives all claims to moral rights in any Developments. 

(c) All Developments related to any patent, copyright, trade secret, or other intellectual property rights, and related to or useful in the
Company’s business, worked on by the Employee while the Employee is employed by the Company and for a period of one year after the termination or cessation of such employment for any reason shall be presumed to have been created, made,
conceived or reduced to practice during the Employee’s employment with the Company and shall therefore be deemed a Development; provided however that the Employee may overcome the presumption with respect to the period of one year after the
termination or cessation of employment by proving that such creation, making, conception or reduction to practice occurred only following termination of his or her employment with the Company and without the use of the Company’s tools, devices,
equipment or Proprietary Information. 
 (d) The Employee agrees to cooperate fully with the Company, both during and after his/her
employment with the Company, at the Company’s expense, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to
Developments. The Employee shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company may deem
necessary or desirable in order to protect its rights and interests in any Development. 
 4. Non-Competition and Non-Solicitation.
While the Employee is employed by the Company and for a period of one year after the termination or cessation of such employment for any reason, the Employee will not directly or indirectly: 

  
 -3- 

 (a) Engage or assist others in engaging in any Competing Organization (whether as owner, partner,
officer, director, employee, consultant, investor, lender or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held company). 

The term “Competing Organization” means any person, entity or organization engaged in, or about to become engaged in, research on or the
acquisition, development, production, distribution, marketing, or providing of a product, process or service that competes or is reasonably expected to compete with a material product, process or service of the Company or being developed by the
Company, but specifically excludes pulmonary delivery therapies utilized in products, processes or services not substantially similar to those produced, marketed, distributed or developed by the Company. However, this paragraph 4(a) shall not
preclude the Employee from (i) becoming an employee of, consultant to, or from otherwise providing services to, a separate division or operating unit of a multi-divisional business or enterprise (a “Division”) if (x) the Division
by which the Employee is employed or engaged, or to which the Employee provides services, is not (if treated by itself as an independent entity) a Competing Organization, and (y) the Employee does not provide services, directly or indirectly,
to any other division or operating unit of such multi-divisional business or enterprise that is a Competing Organization (if treated by itself as an independent entity) or (ii) becoming an employee in the capacity as a senior executive of a
multi-divisional business or enterprise that includes within its organizational structure a business unit that is a Competing Organization (a “Unit”), provided that Employee does not have day to day supervisory or first line
decision-making authority with regard to such Unit. 
 (b) Either alone or in association with others, solicit, divert or take away, or
attempt to divert or take away, the business or patronage of any of the clients, customers, or business partners of the Company that were materially contacted, solicited, or served by the Employee directly or the Company during the 12-month period
prior to the termination or cessation of the Employee’s employment with the Company; or 
 (c) Either alone or in association with
others (i) solicit, induce or attempt to induce, any employee or independent contractor of the Company to terminate his or her employment or other engagement with the Company, or (ii) solicit or attempt to solicit any person who was
employed or otherwise engaged by the Company at any time during the term of the Employee’s employment with the Company; provided, that this clause (ii) shall not apply to the solicitation of any individual whose employment or other
engagement with the Company has been terminated for a period of six months or longer or who was terminated by the Company involuntarily. However, this paragraph 4(c) shall not apply to (I) general advertising or solicitation not specifically
targeted at the Company, its employees or independent contractors, (II) the Employee serving as a reference, upon request, for any employee or independent contractor of the Company, and (III) actions taken by any person or entity with which the
Employee is associated if the Employee is not personally involved in any manner in the hiring, recruitment, solicitation or engagement of any such individual (including but not limited to identifying any such individual for hiring, recruitment,
solicitation or engagement). 

  
 -4- 

 5. Other Agreements. 

The Employee represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms of any
agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his/her employment with the Company, to refrain from competing, directly or
indirectly, with the business of such previous employer or any other party or to refrain from soliciting employees, customers or suppliers of such previous employer or other party. The Employee further represents that his/her performance of all the
terms of this Agreement and the performance of his/her duties as an employee of the Company do not and will not conflict with or breach any agreement with any prior employer or other party to which the Employee is a party (including without
limitation any nondisclosure or non-competition agreement), and that the Employee will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.

 6. United States Government Obligations. 

The Employee acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or
agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. The Employee agrees to be bound by all such
obligations and restrictions that are made known to the Employee and to take all action necessary to discharge the obligations of the Company under such agreements. 

7. Miscellaneous. 
 (a)
Equitable Remedies. The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are considered by the Employee to be reasonable for such purpose. The Employee agrees that any
breach of this Agreement is likely to cause the Company substantial and irrevocable damage that is difficult to measure. Therefore, in the event of any such breach or threatened breach, the Employee agrees that the Company, in addition to such other
remedies which may be available, shall have the right to obtain an injunction from a court restraining such a breach or threatened breach and the right to specific performance of the provisions of this Agreement and the Employee hereby waives the
adequacy of a remedy at law as a defense to such relief. 
 (b) Obligations to Third Parties. The Employee acknowledges and
represents that this agreement and the Employee’s employment with the Company will not violate any continuing obligation the Employee has to any former employer or other third party. 

(c) Disclosure of this Agreement. The Employee hereby authorizes the Company to notify others, including but not limited to customers
of the Company and any of the Employee’s future employers or prospective business associates, of the terms and existence of this Agreement and the Employee’s continuing obligations to the Company hereunder. 

(d) No Employment Contract and No License. The Employee acknowledges that this Agreement does not constitute a contract of employment,
does not imply that the Company will continue his/her employment for any period of time and does not change the at-

  
 -5- 

 
will nature of his/her employment. The Employee further acknowledges that no license to any of the Company’s trademarks, patents, copyrights or other proprietary rights is either granted or
implied by the Employee’s access to and utilization of the Proprietary Information or Developments. 
 (e) Successors and
Assigns. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the
Company’s assets or business, provided, however, that the obligations of the Employee are personal and shall not be assigned by him or her and the Company may assign its rights under Section 4 only to a successor to all or substantially
all of its business. The Employee expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate thereof to whose employ the Employee may be transferred without the necessity that
this Agreement be re-signed at the time of such transfer, provided that the provisions of Section 4 shall be limited to the products, processes, services, clients, customers, business partners, employees, former employees, contractors and
former contractors of the Company and not the acquiror. 
 (f) Interpretation. If any restriction set forth in Section 4 is
found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum
period of time, range of activities or geographic area as to which it may be enforceable. 
 (g) Severability. In case any provision
of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

(h) Waivers. No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any
other right. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion. 

(i) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts
(without reference to the conflicts of laws provisions thereof). Any action, suit, or other legal proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of
the Commonwealth of Massachusetts (or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court. The Company and the Employee each hereby irrevocably waive any
right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement. 
 (j)
Entire Agreement; Amendment. This Agreement supersedes all prior agreements, written or oral, between the Employee and the Company relating to the subject matter of this Agreement. This Agreement may not be modified, changed or discharged in
whole or in part, except by an agreement in writing signed by the Employee and the Company. The 

  
 -6- 

 
Employee agrees that any change or changes in his/her duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement. 

(k) Captions. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or
affect the scope or substance of any section of this Agreement. 
 (l) Application in California. While the Employee is employed by
the Company in California, and following the termination or cessation of such employment if the Employee is employed by the Company in California at the time of such termination or cessation, (i) the post-employment aspects of paragraph 3(c)
and paragraph 4(a) shall be disregarded, and shall not apply to the Employee, and (ii) the post-employment aspects of paragraph 4(b) shall be disregarded, and shall not apply to the Employee, provided however that the Employee shall not
directly or indirectly use Proprietary Information to engage in activities described in paragraph 4(b). 
 THE EMPLOYEE ACKNOWLEDGES THAT
HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT. 
  

									
		 		 		 	CIVITAS THERAPEUTICS, INC.
					
	Date:	 	  
	 		 	By:	 	  

					
		 		 		 		 	  

					
		 		 		 		 	(print name and title)
				
		 		 		 	[NAME OF EMPLOYEE]
				
	Date:	 	  
	 		 	  

 [Signature Page to Invention, Non-Disclosure, Non-Competition and Non-Solicitation Agreement] 

  
 -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]